Mankind Pharma Ties Up With Chinese Firm For Two Insulin Products
Add Preferred News Source
Mankind Pharma is widening its diabetes care portfolio through a new India-focused partnership with China’s Chongqing Chenan Biopharmaceutical. The agreement covers two insulin analogues for commercialisation in India.
Mankind Pharma Limited has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical Co. Limited for two insulin analogues in India. The company announced the agreement on 20 August 2026, with the products aimed at the diabetes care segment.
The agreement covers insulin degludec and an insulin degludec combination product.
Mankind Pharma’s share price closed at ₹2,385, down ₹9.00, or 0.38%, on the National Stock Exchange (NSE).
Partnership Aligns With Mankind Pharma Licensing Strategy
Mankind Pharma said the agreement is part of its wider approach of using strategic partnerships and in-licensing opportunities to access global innovation. The company described the collaboration as aligned with this broader strategy.
Atish Majumdar, Senior President, Sales and Marketing, at Mankind Pharma, said the partnership is intended to expand access to advanced therapies in India while strengthening the company's presence in injectable diabetes care.
Commercialisation Plans Remain The Next Focus
The agreement gives Mankind Pharma exclusive rights to commercialise and market the two insulin products in India. The focus now shifts to bringing the licensed therapies into the company's diabetes care portfolio.
The financial terms of the agreement have not been disclosed in the information provided by the source. The company has also not provided further details on the expected commercial rollout of the two products.
Also Read - PlaySimple Games Files For ₹3,150 Crore IPO
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
